InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by ENLOE J DAVID JR, Chairman & CEO. Director active across 2 companies, notably Recro Pharma, Inc.. In total, 15 disclosures have been logged. Breakdown: 12 buys · 0 sell. Total volume traded: €14k. History available since 12 November 2021. The latest transaction was disclosed on 15 June 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
1,562 shares@ US$0.680.0000% mcap2.8% of flowCommon StockSEC:0001062993-22-015149:0
Ideal exit: 12 Mar 2023 (T+270)
1,086 shares@ US$0.9610.0000% mcap2.8% of flowCommon StockSEC:0001062993-22-012918:0
Ideal exit: 10 Feb 2023 (T+270)
625 shares@ US$1.630.0000% mcap2.6% of flowCommon StockSEC:0001062993-22-010465:0
Ideal exit: 13 Jan 2023 (T+270)
22,590 shares@ US$1.650.0000% mcap91.7% of flowCommon StockSEC:0001062993-22-009516:0
512 shares@ US$1.968.1% of flowCommon StockSEC:0001062993-22-008073:0
Ideal exit: 10 Dec 2022 (T+270)
571 shares@ US$1.7717.2% of flowCommon StockSEC:0001062993-22-004789
Ideal exit: 12 Nov 2022 (T+270)
571 shares@ US$1.777.9% of flowCommon StockSEC:0001062993-22-004789:0
Ideal exit: 12 Nov 2022 (T+270)
66,007 sharesCommon StockSEC:0000899243-22-003083:0
66,007 sharesCommon StockSEC:0000899243-22-003083
602 shares@ US$1.6817.1% of flowCommon StockSEC:0000899243-22-002423
Ideal exit: 15 Oct 2022 (T+270)
602 shares@ US$1.687.8% of flowCommon StockSEC:0000899243-22-002423:0
Ideal exit: 15 Oct 2022 (T+270)
617 shares@ US$1.6117.0% of flowCommon StockSEC:0000899243-21-048870
Ideal exit: 11 Sept 2022 (T+270)
617 shares@ US$1.617.8% of flowCommon StockSEC:0000899243-21-048870:0
Ideal exit: 11 Sept 2022 (T+270)
1,725 shares@ US$1.678422.4% of flowCommon StockSEC:0000899243-21-044709:0
Ideal exit: 9 Aug 2022 (T+270)
1,725 shares@ US$1.678448.7% of flowCommon StockSEC:0000899243-21-044709
Ideal exit: 9 Aug 2022 (T+270)
15 of 15 declarations
About ENLOE J DAVID JR
David J Enloe Jr is an executive at Recro Pharma, Inc.
